Redmile Group, Llc - Net Worth and Insider Trading

Redmile Group, Llc Net Worth

The estimated net worth of Redmile Group, Llc is at least $1.1 Billion dollars as of 2024-04-25. Redmile Group, Llc is the 10% Owner of Array BioPharma Inc and owns about 16,658,072 shares of Array BioPharma Inc (ARRY) stock worth over $649 Million. Redmile Group, Llc is the 10% Owner of Amicus Therapeutics Inc and owns about 12,956,446 shares of Amicus Therapeutics Inc (FOLD) stock worth over $137 Million. Redmile Group, Llc is also the Director, 10% Owner of Augmedix Inc and owns about 25,850,163 shares of Augmedix Inc (AUGX) stock worth over $74 Million. Besides these, Redmile Group, Llc also holds Fate Therapeutics Inc (FATE) , Shattuck Labs Inc (STTK) , Zymeworks Inc (ZYME) , Absci Corp (ABSI) , Entrada Therapeutics Inc (TRDA) , IGM Biosciences Inc (IGMS) , Verve Therapeutics Inc (VERV) , Aprea Therapeutics Inc (APRE) , Invivyd Inc (IVVD) , Xeris Biopharma Holdings Inc (XERS) , Neoleukin Therapeutics Inc (NLTX) , Syros Pharmaceuticals Inc (SYRS) . Details can be seen in Redmile Group, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Redmile Group, Llc has not made any transactions after 2024-03-01 and currently still holds the listed stock(s).

Transaction Summary of Redmile Group, Llc

To

Redmile Group, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Redmile Group, Llc owns 35 companies in total, including Shattuck Labs Inc (STTK) , IGM Biosciences Inc (IGMS) , and Kymera Therapeutics Inc (KYMR) among others .

Click here to see the complete history of Redmile Group, Llc’s form 4 insider trades.

Insider Ownership Summary of Redmile Group, Llc

Ticker Comapny Transaction Date Type of Owner
STTK Shattuck Labs Inc 2020-10-14 director & 10 percent owner
IGMS IGM Biosciences Inc 2023-06-29 director & 10 percent owner
KYMR Kymera Therapeutics Inc 2020-08-20 10 percent owner
ALVR AlloVir Inc 2020-07-29 10 percent owner
ANNX Annexon Inc 2020-07-23 10 percent owner
NRIX Nurix Therapeutics Inc 2020-07-23 10 percent owner
RPTX Repare Therapeutics Inc 2020-06-18 10 percent owner
FATE Fate Therapeutics Inc 2023-12-26 director & 10 percent owner
PLRX Pliant Therapeutics Inc 2020-06-02 10 percent owner
NLTX Neoleukin Therapeutics Inc 2020-04-02 10 percent owner
BEAM Beam Therapeutics Inc 2020-02-05 10 percent owner
CABA Cabaletta Bio Inc 2019-10-24 10 percent owner
ALDR Alder BioPharmaceuticals Inc 2019-10-22 director
APRE Aprea Therapeutics Inc 2020-12-28 10 percent owner
BCEL Atreca Inc 2019-06-19 10 percent owner
AKRO Akero Therapeutics Inc 2019-06-19 10 percent owner
STOK Stoke Therapeutics Inc 2019-06-18 10 percent owner
HOOK HOOKIPA Pharma Inc 2019-04-17 10 percent owner
XERS Xeris Biopharma Holdings Inc 2019-02-19 10 percent owner
TCRR TCR2 Therapeutics Inc 2019-02-13 10 percent owner
VAPO Vapotherm Inc 2018-11-13 10 percent owner
GRTS Gritstone Bio Inc 2018-09-27 10 percent owner
REPL Replimune Group Inc 2018-07-19 10 percent owner
ALLK Allakos Inc 2018-07-18 10 percent owner
SYRS Syros Pharmaceuticals Inc 2016-07-06 10 percent owner
FOLD Amicus Therapeutics Inc 2016-06-03 10 percent owner
MDVLQ MedAvail Holdings Inc 2020-11-17 director & 10 percent owner
ABSI Absci Corp 2024-03-01 director & 10 percent owner
TRDA Entrada Therapeutics Inc 2021-11-02 10 percent owner
AUGX Augmedix Inc 2023-11-20 director & 10 percent owner
SNCE Science 37 Holdings Inc 2021-10-06 director & 10 percent owner
IVVD Invivyd Inc 2021-08-10 10 percent owner
VERV Verve Therapeutics Inc 2021-06-21 10 percent owner
ZYME Zymeworks Inc 2022-10-13 10 percent owner
RYZB RayzeBio inc 2023-09-14 10 percent owner

Redmile Group, Llc Latest Holdings Summary

Redmile Group, Llc currently owns a total of 15 stocks. Among these stocks, Redmile Group, Llc owns 16,658,072 shares of Array BioPharma Inc (ARRY) as of September 28, 2016, with a value of $649 Million and a weighting of 56.73%. Redmile Group, Llc owns 12,956,446 shares of Amicus Therapeutics Inc (FOLD) as of June 3, 2016, with a value of $137 Million and a weighting of 11.94%. Redmile Group, Llc also owns 25,850,163 shares of Augmedix Inc (AUGX) as of November 20, 2023, with a value of $74 Million and a weighting of 6.44%. The other 12 stocks Fate Therapeutics Inc (FATE) , Shattuck Labs Inc (STTK) , Zymeworks Inc (ZYME) , Absci Corp (ABSI) , Entrada Therapeutics Inc (TRDA) , IGM Biosciences Inc (IGMS) , Verve Therapeutics Inc (VERV) , Aprea Therapeutics Inc (APRE) , Invivyd Inc (IVVD) , Xeris Biopharma Holdings Inc (XERS) , Neoleukin Therapeutics Inc (NLTX) , Syros Pharmaceuticals Inc (SYRS) have a combined weighting of 24.89% among all his current holdings.

Latest Holdings of Redmile Group, Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ARRY Array BioPharma Inc 2016-09-28 16,658,072 38.95 648,831,904
FOLD Amicus Therapeutics Inc 2016-06-03 12,956,446 10.54 136,560,941
AUGX Augmedix Inc 2023-11-20 25,850,163 2.85 73,672,965
FATE Fate Therapeutics Inc 2023-12-26 13,180,388 4.30 56,675,668
STTK Shattuck Labs Inc 2020-10-14 5,619,914 9.90 55,637,149
ZYME Zymeworks Inc 2022-10-13 6,075,918 8.55 51,949,099
ABSI Absci Corp 2024-03-01 8,253,316 4.53 37,387,521
TRDA Entrada Therapeutics Inc 2021-11-02 1,954,420 12.43 24,293,441
IGMS IGM Biosciences Inc 2023-06-29 2,974,186 7.96 23,674,521
VERV Verve Therapeutics Inc 2021-06-21 1,936,530 6.58 12,742,367
APRE Aprea Therapeutics Inc 2020-12-28 1,768,718 5.17 9,144,272
IVVD Invivyd Inc 2021-08-10 3,390,960 2.13 7,222,745
XERS Xeris Biopharma Holdings Inc 2019-02-19 3,000,642 1.76 5,281,130
NLTX Neoleukin Therapeutics Inc 2020-04-02 202,061 3.49 705,193
SYRS Syros Pharmaceuticals Inc 2016-07-06 4,979 5.07 25,244

Holding Weightings of Redmile Group, Llc


Redmile Group, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Redmile Group, Llc has made a total of 0 transactions in Array BioPharma Inc (ARRY) over the past 5 years. The most-recent trade in Array BioPharma Inc is the sale of 2,492,578 shares on September 28, 2016, which brought Redmile Group, Llc around $16 Million.

According to the SEC Form 4 filings, Redmile Group, Llc has made a total of 0 transactions in Amicus Therapeutics Inc (FOLD) over the past 5 years. The most-recent trade in Amicus Therapeutics Inc is the acquisition of 66,300 shares on June 3, 2016, which cost Redmile Group, Llc around $477,360.

According to the SEC Form 4 filings, Redmile Group, Llc has made a total of 3 transactions in Augmedix Inc (AUGX) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Augmedix Inc is the acquisition of 1,500,000 shares on November 20, 2023, which cost Redmile Group, Llc around $6 Million.

More details on Redmile Group, Llc's insider transactions can be found in the Insider Trading History of Redmile Group, Llc table.

Insider Trading History of Redmile Group, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Redmile Group, Llc Trading Performance

GuruFocus tracks the stock performance after each of Redmile Group, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Redmile Group, Llc is 10.23%. GuruFocus also compares Redmile Group, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Redmile Group, Llc within 3 months outperforms 12 times out of 35 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Redmile Group, Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Redmile Group, Llc

Average Return

22.11%

Average return per transaction

Outperforming Transactions

53%

17 out of 32 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 10.45 10.23 1.17 22.11 6.78 2.72
Relative Return to S&P 500(%) 8.9 4.91 -3.17 8.56 -3.94 -9.29

Redmile Group, Llc Ownership Network

Ownership Network List of Redmile Group, Llc

No Data

Ownership Network Relation of Redmile Group, Llc


Redmile Group, Llc Owned Company Details

What does Shattuck Labs Inc do?

Who are the key executives at Shattuck Labs Inc?

Redmile Group, Llc is the director & 10 percent owner of Shattuck Labs Inc. Other key executives at Shattuck Labs Inc include See Remarks Stephen Stout , See Remarks Andrew R Neill , and Chief Technical Officer Abhinav A. Shukla .

Shattuck Labs Inc (STTK) Insider Trades Summary

Over the past 18 months, Redmile Group, Llc made no insider transaction in Shattuck Labs Inc (STTK). Other recent insider transactions involving Shattuck Labs Inc (STTK) include a net sale of 25,000 shares made by Andrew R Neill , and a net sale of 16,004 shares made by Stephen Stout .

In summary, during the past 3 months, insiders sold 16,004 shares of Shattuck Labs Inc (STTK) in total and bought 0 shares, with a net sale of 16,004 shares. During the past 18 months, 41,004 shares of Shattuck Labs Inc (STTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 41,004 shares.

Shattuck Labs Inc (STTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Shattuck Labs Inc Insider Transactions

No Available Data

Redmile Group, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Redmile Group, Llc. You might contact Redmile Group, Llc via mailing address: One Letterman Drive, Building D, Suite D3-300, San Francisco Ca 94129.

Discussions on Redmile Group, Llc

No discussions yet.